Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Seroprevalence Study in French Guiana (EPI-COVID-POP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04490850
Recruitment Status : Recruiting
First Posted : July 29, 2020
Last Update Posted : July 29, 2020
Sponsor:
Collaborators:
Institut Pasteur de la Guyane
Laboratoire de biologie médicale, Institut Pasteur de la Guyane
Laboratoire de biologie médicale de Kourou, French Guiana
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana
Laboratoire Eurofins Guyane de Rémire-Montjoly, French Guiana
Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana
Information provided by (Responsible Party):
Institut Pasteur

Brief Summary:
Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Condition or disease Intervention/treatment Phase
Coronavirus Infection Severe Acute Respiratory Syndrome SARS-CoV Infection Covid19 Procedure: Blood sample Not Applicable

Detailed Description:

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

This study is a interventional study that present minimal risks and constraints.

The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1500 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: COVID-19 Seroprevalence Study in French Guiana
Actual Study Start Date : July 15, 2020
Estimated Primary Completion Date : July 15, 2021
Estimated Study Completion Date : July 15, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Participants
Blood sample
Procedure: Blood sample
Blood sample




Primary Outcome Measures :
  1. Measure of the COVID-19 immunity of the population [ Time Frame: 1 year ]
    The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies


Secondary Outcome Measures :
  1. Evaluation of the level of asymptomatic and pauci-symptomatic infections [ Time Frame: 1 year ]
    The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
  • State of health compatible with a blood sample as defined in the protocol

Exclusion Criteria:

  • Inability to consent
  • Person under guardianship or curatorship
  • Known pathology or a health problem contraindicated with the collect of blood sample.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04490850


Contacts
Layout table for location contacts
Contact: Claude Flamand, PhD +33 5 94 29 26 15 cflamand@pasteur-cayenne.fr

Locations
Layout table for location information
French Guiana
Centre Hospitalier Andrée Rosemon Recruiting
Cayenne, French Guiana
Contact: Véronique Servas       veronique.servas@ch-cayenne.fr   
Laboratoire de biologie méicale, Institut Pasteur de la Guyane Recruiting
Cayenne, French Guiana
Contact: Emmanuel Belliard       eballiard@pasteur-cayenne.fr   
Laboratoires Eurofins Guyane Recruiting
Cayenne, French Guiana
Contact: Didier Didier       didiermusso@eurofins.com   
Laboratoire de biologie médicale de Kourou Recruiting
Kourou, French Guiana
Contact: Thierry Carage       tpcarage@orange.fr   
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni Recruiting
Saint-Laurent du Maroni, French Guiana
Contact: Jean-François Carod       jf.carod@ch-ouestguyane.fr   
Sponsors and Collaborators
Institut Pasteur
Institut Pasteur de la Guyane
Laboratoire de biologie médicale, Institut Pasteur de la Guyane
Laboratoire de biologie médicale de Kourou, French Guiana
Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana
Laboratoire Eurofins Guyane de Rémire-Montjoly, French Guiana
Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana
Investigators
Layout table for investigator information
Principal Investigator: Claude Flamand, PhD Institut Pasteur de la Guyane, Head of Epidemiology Unit
Layout table for additonal information
Responsible Party: Institut Pasteur
ClinicalTrials.gov Identifier: NCT04490850    
Other Study ID Numbers: 2020-048
First Posted: July 29, 2020    Key Record Dates
Last Update Posted: July 29, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Pasteur:
SARS-CoV-2
COVID-19
Serology
French Guiana
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Coronavirus Infections
Severe Acute Respiratory Syndrome
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases